Business
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Cali
About this update from Metagenomi Therapeutics, Inc.
[{"type":"image","alt":"Metagenomi Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Metagenomi Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/8fe98471f37fe1fb8aa0158e0a6364b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DLX3m7aClZGxnthC8I74Mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcw/https://media.zenfs.com/en/globenewswire.com/8fe98471f37fe1fb8aa0158e0a6364b1","width":300,"height":50},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/DLX3m7aClZGxnthC8I74Mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcw/https://media.zenfs.com/en/globenewswire.com/8fe98471f37fe1fb8aa0158e0a6364b1","width":300,"height":50}},"lazy":false},{"type":"text","content":"On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026","length":147,"tagName":"p"},{"type":"text","content":"Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency","length":168,"tagName":"p"},{"type":"text","content":"$140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027","length":170,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.","length":351,"tagName":"p"},{"type":"text","content":"“We remain diligently focused on advancing our core genome-editing technologies, led by our MGX-001 program for hemophilia A, which remains on track for regulatory submission in the fourth quarter of this year and first-in-human studies in 2027,” said Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of Metagenomi Therapeutics. “The promise of our novel technology, most recently highlighted by a Nature publication, in addition to the encouraging preclinical data and continued IND-enabling execution, gives us confidence in our goal to...